Lead Product(s) : Ifetroban
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cumberland Pharma Receives FDA Orphan Drug Designation for Duchenne Dystrophy Treatment
Details : Ifetroban is a potent and selective thromboxane-prostanoid receptor (TPr) antagonist being investigated for cardiomyopathy associated with Duchenne muscular dystrophy.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 06, 2024
Lead Product(s) : Ifetroban
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?